Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease: the EMBRACE study

References

• Geula C, Mesulam MM. Cholinergic systems and related neuropathological predilection patterns in Alzheimer's disease. In: Terry RD, Katzman R, Bick KL (eds). Alzheimer's Disease. New York: Raven Press, 1994:263-91
   Google Scholar
• Martin BC, Ricci JF, Kotzan JA, et al. The net cost of Alzheimer disease and related dementia: a population-based study of Georgia Medicaid recipients. Alzheimer Dis Assoc Disord 2000;14:151-9
   PubMed Web of Science ®Google Scholar
• Sloan FA, Taylor DH Jr. Effect of Alzheimer disease on the cost of treating other diseases. Alzheimer Dis Assoc Disord 2002;16:137-43
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22
   PubMed Web of Science ®Google Scholar
• Alzheimer's Association. 2011 Alzheimer's Disease Facts and Figures. 7. Alzheimer's Association, 2011
   Google Scholar
• Alzheimer Society Canada. Rising Tide: The Impact of Dementia on Canadian Society. Available at: http://www.alzheimer.ca/en/Get-involved/Raise-your-voice/Rising-Tide [Last accessed 4 February 2013]
   Google Scholar
• Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003;4:131-8
   PubMed Web of Science ®Google Scholar
• Giacobini E, Spiegel R, Enz A, et al. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 2002;109:1053-65
   PubMed Web of Science ®Google Scholar
• Mesulam M, Guillozet A, Shaw P, et al. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002;9:88-93
   PubMed Web of Science ®Google Scholar
• Darvesh S, Hopkins D. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 2003;463:25-43
   PubMed Web of Science ®Google Scholar
• Grossberg GT, Stahelin HB, Messina JC, et al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000;15:242-7
   PubMed Web of Science ®Google Scholar
• Bullock R, Touchon J, Bergman J, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21:1317-27
   PubMed Web of Science ®Google Scholar
• Gauthier S, Juby A, Morelli L, et al; EXTEND Investigators. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND study. Curr Med Res Opin 2006;22:2251-65
   PubMed Web of Science ®Google Scholar
• Tekin S, Fairbanks LA, O'Connor S, et al. Activities of daily living in Alzheimer's disease: neuropsychiatric, cognitive, and medical illness influences. Am J Geriatr Psychiatry 2001;9:81-6
   PubMed Web of Science ®Google Scholar
• Farlow MR, Hake A, Messina J, et al. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001;58:417-22
   PubMed Web of Science ®Google Scholar
• Auriacombe S, Pere JJ, Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18:129-38
   PubMed Web of Science ®Google Scholar
• Lopez-Pousa S, Turon-Estrada A, Garre-Olmo J, et al. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. Dement Geriatr Cogn Disord 2005;19:189-95
   PubMed Web of Science ®Google Scholar
• Wilkinson DG, Francis PT, Schwam E, et al. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004;21:453-78
   PubMed Web of Science ®Google Scholar
• Aguglia E, Onor ML, Saina M, et al. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 2004;20:1747-52
   PubMed Web of Science ®Google Scholar
• Mossello E, Tonon E, Caleri V, et al. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a ‘real world’ study. Arch Gerontol Geriatr Suppl 2004;38:297-307
   Google Scholar
• Grossberg GT, Sadowsky C, Olin JT. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease. Int J Clin Pract 2010;64:651-60
   PubMed Web of Science ®Google Scholar
• Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-67
   PubMed Web of Science ®Google Scholar
• Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007;69(4 Suppl 1):S14-22
   PubMed Web of Science ®Google Scholar
• Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007;23:2705-13
   PubMed Web of Science ®Google Scholar
• Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:485-91
   PubMed Web of Science ®Google Scholar
• Nagy B, Brennan A, Brandtmuller A, et al. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. Int J Geriatr Psychiatry 2011;26:483-94
   PubMed Web of Science ®Google Scholar
• Bond M, Rogers G, Peters J, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess 2012;16:1-470
   PubMed Web of Science ®Google Scholar
• Alva G, Grossberg GT, Schmitt FA, et al. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. Int J Geriatr Psychiatry 2011;26:356-63
   PubMed Web of Science ®Google Scholar
• Articus K, Baier M, Tracik F, et al. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease. Int J Clin Pract 2011;65:790-6
   PubMed Web of Science ®Google Scholar
• Cummings J, Froelich L, Black SE, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer's disease. Dement Geriatr Cogn Disord 2012;33:341-53
   PubMed Web of Science ®Google Scholar
• Farlow MR, Grossberg G, Gauthier S, et al. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Curr Med Res Opin 2010;26:2441-7
   PubMed Web of Science ®Google Scholar
• Grossberg G, Sadowsky C, Frostl H, et al. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 2009;23:158-64
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Imai Y, Shigeta M, et al. A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dement Geriatr Cogn Dis Extra 2011;1:163-79
   PubMedGoogle Scholar
• Sadowsky CH, Farlow MR, Meng X, et al. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. Int J Clin Pract 2010;64:188-93
   PubMed Web of Science ®Google Scholar
• Choi SH, Park KW, Na DL, et al. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. Curr Med Res Opin 2011;27:1375-83
   PubMed Web of Science ®Google Scholar
• Dhillon S. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type. Drugs 2011;71:1209-31
   PubMed Web of Science ®Google Scholar
• Farlow MR, Alva G, Meng X, Olin JT. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Curr Med Res Opin 2010;26:263-9
   PubMed Web of Science ®Google Scholar
• Molloy DW, Alemayehu E, Roberts R. Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination. Am J Psychiatry 1991;148:102-5
   PubMed Web of Science ®Google Scholar
• Vertesi A, Lever JA, Molloy DW, et al. Standardized Mini-Mental State Examination. Use and interpretation. Can Fam Physician 2001;47:2018-23
   PubMed Web of Science ®Google Scholar
• Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008;148:370-8
   PubMed Web of Science ®Google Scholar
• Kupper LL, Hafner KB. How appropriate are popular sample size formulas? Am Statistician 1989;43:101-5
   Web of Science ®Google Scholar
• Grossberg G, Meng X, Olin JT. Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2011;26:65-71
   PubMed Web of Science ®Google Scholar
• Sadowsky C, Perez JA, Bouchard RW, et al. Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch. CNS Neurosci Ther 2010;16:51-60
   PubMed Web of Science ®Google Scholar
• Sadowsky CH, Dengiz A, Meng X, et al; US38 Study Group. Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results. Prim Care Companion J Clin Psychiatry 2010;2:e1-e8
   Google Scholar
• Seibert J, Tracik F, Articus K, et al. Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer's disease in daily practice. Neuropsychiatr Dis Treat 2012;8:141-7
   PubMed Web of Science ®Google Scholar
• Wattmo C, Wallin AK, Minthon L. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort. BMC Neurol 2012;2:134
   Google Scholar
• Gauthier S, Juby A, Rehel B, et al. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease. Int J Clin Pract 2007;61:886-95
   PubMed Web of Science ®Google Scholar
• Gauthier S, Juby A, Dalziel W, et al; EXPLORE investigators. Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE). Curr Med Res Opin 2010;26:1149-60
   PubMed Web of Science ®Google Scholar
• Pregelj P. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions. Psychogeriatrics 2012;12:165-71
   PubMed Web of Science ®Google Scholar
• Minthon L, Wallin AK, Eriksson S, et al. Long-term rivastigmine treatment in a routine clinical setting. Acta Neurol Scand 2009;119:180-5
   PubMed Web of Science ®Google Scholar
• Tian H, Abouzaid S, Chen W, et al. Patient adherence to transdermal rivastigmine after switching from oral donepezil: a retrospective claims database study. Alzheimer Dis Assoc Disord 2012;[Epub ahead of print. 2012 Aug 12.]
   Google Scholar
• Salzman C. Medication compliance in the elderly. J Clin Psychiatry 1995;56(Suppl 1):18-22
   PubMed Web of Science ®Google Scholar
• Alzheimer's Association and National Alliance for Caregiving. National Survey. 2004
   Google Scholar
• Slattum PW, Johnson MA. Caregiver burden in Alzheimer's disease. Consult Pharm 2004;19:352-62
   PubMedGoogle Scholar
• Travis SS, Kao HF, Acton GJ. Helping family members manage medication administration hassles. J Psychosoc Nurs Ment Health Serv 2005;43:13-15
   PubMedGoogle Scholar
• McGraw C, Drennan V. Self-administration of medicine and older people. Nurs Stand 2001;15:33-6
   PubMedGoogle Scholar
• Ryan AA. Medication compliance and older people: a review of the literature. Int J Nurs Stud 1999;36:153-62
   PubMed Web of Science ®Google Scholar
• Sink KM, Covinsky KE, Barnes DE, et al. Caregiver characteristics are associated with neuropsychiatric symptoms of dementia. J Am Geriatr Soc 2006;54:796-803
   PubMed Web of Science ®Google Scholar
• Cramer JA. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am J Manag Care 1998;4:1563-8
   PubMed Web of Science ®Google Scholar
• Richter A, Anton SE, Koch P, et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-35
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Boada M, Arranz FJ. Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine. Dement Geriatr Cogn Disord 2013;35:23-33
   PubMed Web of Science ®Google Scholar